Halozyme Therapeutics, Inc. (HALO) Stock Forecasts
Halozyme Therapeutics Inc. (HALO) has received a revised stock forecast from Argus, which lowered its target price to $123.00. The biotechnology company, focused on oncology therapies, is currently trading at $109.86. The report from September 30, 2026, is part of a quantitative analysis available to premium subscribers.
Halozyme adds James Daly to its Board of Directors
Halozyme (HALO) has announced the election of James Daly to its Board of Directors, effective September 28, 2026. He will initially not be assigned to any Board committee. This information was disclosed in an SEC Filing (8-K) on September 30, 2026.
Halozyme appoints Jim Daly to board of directors
Halozyme Therapeutics, Inc. (NASDAQ:HALO) has announced the appointment of James Daly to its board of directors. Daly brings over 30 years of commercial leadership experience in the biopharmaceutical industry, having previously served on Halozyme’s board and held senior positions at companies like Incyte Corporation, Amgen, and Glaxo Wellcome/GlaxoSmithKline. Halozyme specializes in drug delivery technologies, including ENHANZE, which is licensed to numerous pharmaceutical companies globally.
Halozyme Announces Appointment of Jim Daly to its Board of Directors
Halozyme Therapeutics, Inc. has appointed James "Jim" Daly to its Board of Directors. Daly brings over three decades of commercial leadership experience in biopharmaceuticals, having successfully launched respiratory, oncology, and immunology therapies. His expertise is expected to be invaluable as Halozyme expands its subcutaneous drug delivery technologies, including ENHANZE, Hypercon, and Aerocon.
Halozyme Therapeutics, Inc. Appoints James "Jim" Daly to Its Board of Directors
Halozyme Therapeutics, Inc. has announced the appointment of James "Jim" Daly to its Board of Directors. Mr. Daly is a highly experienced biopharmaceutical executive with over three decades of commercial leadership, including successful launches of respiratory, oncology, and immunology therapies. He has previously served on Halozyme's board and held senior commercial roles at Incyte Corporation, Amgen, and Glaxo Wellcome/GlaxoSmithKline.
Price to cash flow ratio of Halozyme Therapeutics, Inc. – HAN:RV7
The article focuses on the price to cash flow ratio of Halozyme Therapeutics, Inc. (HAN:RV7) on the Hannover Stock Exchange. It indicates that the market is currently closed with no trades. The article also provides general navigation and company information for TradingView, where this financial data is presented.
Halozyme Therapeutics, Inc. Revenue Breakdown – HAN:RV7
Halozyme Therapeutics, Inc. (HAN:RV7) generated 1.19 billion EUR in revenue last year, primarily from its Proprietary Enzymes, Devices, Hypercon Technology, and Surf Bio Technology segment. The United States was the largest contributor to this revenue, accounting for 700.70 million EUR. This represents an increase from the previous year's total revenue of 980.78 million EUR.
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
This article examines the hypothetical growth of a $1000 investment in Halozyme Therapeutics (HALO) made a decade ago. It highlights that such an investment would now be worth $9,284.68, an 828.47% gain, significantly outperforming the S&P 500 and gold over the same period. The article also discusses Halozyme's business model, driven by its ENHANZE drug delivery technology and collaborations, as well as potential challenges like biosimilar competition.
Halozyme Therapeutics (HALO) Closes A US$1.3b Note Offering, Is The Upside Already Priced In?
Halozyme Therapeutics (HALO) recently closed a US$1.3 billion convertible note offering due 2033, which introduces new capital but also potential future share dilution. Despite strong past share price performance, the stock currently trades above average analyst targets and is considered 13% overvalued based on a narrative valuation model, which raises questions about its fair value post-financing. Another perspective using a P/E multiple suggests a different valuation picture when compared to peers and its fair ratio.
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?
Halozyme Therapeutics (HALO) shares jumped 3.3% on strong volume, driven by investor optimism regarding its ENHANZE drug-delivery technology collaborations. The company is projected to report significant year-over-year growth in both earnings and revenue, with analysts revising EPS estimates upward. This positive trend in earnings estimate revisions suggests potential for further stock appreciation.
Halozyme Therapeutics Raises $1.5 Billion in 1.50% Convertible Notes, Adds Capped Calls
Halozyme Therapeutics completed a $1.5 billion offering of 1.50% Convertible Senior Notes due 2033, securing approximately $1.471 billion in net proceeds for general corporate uses and potential repurchases of existing notes. To mitigate dilution, the company also entered into capped call transactions with an initial cap price of about $208.39 per share, funded with roughly $187.5 million of the proceeds. This combined financing and hedging strategy is designed to support growth while managing future equity dilution for the company.
Form 8K Halozyme Therapeutics Inc For: 22 September By Investing.com
This article reports on the filing of a Form 8K by Halozyme Therapeutics Inc. for September 22, 2026. The brief announcement is provided by Investing.com, a financial markets news source. No further details about the content of the 8K filing are given within this specific article.
Latham & Watkins Advises on Halozyme Therapeutics, Inc.’s Upsized US$1.3 Billion Convertible Senior Notes Offering
Latham & Watkins LLP advised the initial purchasers in Halozyme Therapeutics, Inc.'s upsized offering of US$1.3 billion aggregate principal amount of 1.5% convertible senior notes due 2033. The offering size was increased from US$1.05 billion, with an additional option for the initial purchasers to buy up to US$200 million more notes. The transaction involved a multidisciplinary team from Latham & Watkins covering capital markets, derivatives, FDA and healthcare regulatory matters, intellectual property, and tax.
Halozyme Therapeutics stock hits all-time high at 111.56 USD By Investing.com
Halozyme Therapeutics stock reached an all-time high of $111.56, demonstrating strong market performance with a 41.38% increase over the past year and a 63% year-to-date return. The company reported impressive Q2 2026 financial results, surpassing Wall Street expectations for both earnings and revenue, leading to a raised full-year outlook. Analysts have reacted positively, with H.C. Wainwright reiterating a Buy rating and Citizens raising its price target, driven by deal momentum and significant royalty revenue growth from new commercial products.
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
Halozyme Therapeutics, Inc. announced the pricing of an upsized private offering of $1.3 billion aggregate principal amount of 1.50% convertible senior notes due 2033, increased from an initial $1.05 billion. The company also granted initial purchasers an option for an additional $200 million. Proceeds will fund capped call transactions, repurchase existing convertible notes due 2027 and 2028, and be used for general corporate purposes.
Halozyme Therapeutics stock hits all-time high at 111.56 USD
Halozyme Therapeutics Inc. stock reached an all-time high of $111.56, marking a significant milestone driven by a 41.38% increase over the past year and a 63% year-to-date return. The company reported strong Q2 2026 financial results, surpassing Wall Street expectations, and raised its full-year outlook. Analysts have reiterated positive ratings and price targets, citing deal momentum and robust growth in partnered drugs.
Halozyme Prices $1.3 Billion Convertible Senior Notes Offering
Halozyme Therapeutics has priced a $1.3 billion offering of convertible senior notes. The company previously announced plans for a $1.05 billion offering of convertible notes. This financial move follows several recent company events, including presentations at investment conferences and changes to its board of directors.
Halozyme Therapeutics Plans $1.05 Billion Offering of Convertible Notes
Halozyme Therapeutics announced its plan to offer $1.05 billion in convertible notes. The company previously priced a larger offering of $1.3 billion convertible senior notes. This financial move follows recent analyst recommendations and earnings reports for Halozyme.
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
Halozyme Therapeutics (HALO) is highlighted as an attractive growth stock due to its strong Zacks Growth Style Score and high Zacks Rank. Key factors include exceptional projected earnings growth of 110.4% for the current year, a high asset utilization ratio of 0.67, and positive earnings estimate revisions, with current-year estimates surging 4.3% in the past month. These elements collectively suggest potential for outperformance for growth investors.
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
Halozyme Therapeutics, Inc. announced a proposed offering of $1.05 billion in convertible senior notes due 2033, with an option for initial purchasers to buy an additional $150 million. The company plans to use a portion of the proceeds to fund capped call transactions and repurchase existing convertible notes due in 2027 and 2028, with the remainder allocated for general corporate purposes. The offering is directed towards "qualified institutional buyers" and is not registered under the Securities Act.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Plans $1.05B Convertible Notes Due 2033
Halozyme Therapeutics, Inc. (NASDAQ:HALO) plans to offer $1.05 billion in convertible senior notes due 2033, with an option for an additional $150 million, to fund capped call transactions, repurchase existing notes from 2027/2028, and for general corporate purposes. This move is considered a typical balance-sheet refinancing, shifting maturities and managing dilution. The final pricing details (coupon, conversion premium, cap) and the size of note repurchases will be crucial in gauging the impact on leverage and potential dilution for the company.
Zacks.com featured highlights include Halozyme Therapeutics, Avnet, BILL and Venture Global
Zacks.com has highlighted four stocks—Halozyme Therapeutics (HALO), Avnet (AVT), BILL Holdings (BILL), and Venture Global (VG)—as top PEG value stocks for strong growth and returns. These companies are recommended for investors seeking value picks with robust earnings growth potential, especially in volatile markets. The article emphasizes the importance of the PEG ratio in identifying intrinsically valuable stocks beyond traditional P/E ratios.
Halozyme president and CEO Helen Torley sells $6.4 million in stock By Investing.com
Helen Torley, President and CEO of Halozyme Therapeutics, Inc., sold approximately $6.4 million worth of company stock between September 9 and September 11, 2026. These transactions, involving 60,000 shares, were conducted under a pre-arranged trading plan and follow a significant surge in the company's stock price. Torley continues to beneficially own 767,780 shares, and the company recently reported strong financial results, surpassing Wall Street expectations, and raised its full-year outlook.
Why (HALO) Price Action Is Critical for Tactical Trading
The article analyzes Halozyme Therapeutics Inc. (NASDAQ: HALO) focusing on its price action for tactical trading. It highlights weak near-term sentiment but compelling upside potential due to the absence of resistance levels above the current price. The analysis includes AI-generated trading strategies for different risk profiles and a multi-timeframe signal analysis, showing divergent sentiment across various horizons.
Halozyme Therapeutics stock hits all-time high at 109.69 USD By Investing.com
Halozyme Therapeutics Inc. stock reached an all-time high of $109.69, reflecting a 46.06% increase over the past year and significant investor confidence. The company's market capitalization stands at $12.4 billion, with recent financial results exceeding Wall Street expectations due to strong royalty revenue and strategic advancements. Analysts maintain positive ratings and raised price targets for the biotech firm.
Halozyme Therapeutics stock hits all-time high at 109.69 USD
Halozyme Therapeutics Inc. (HALO) stock reached an all-time high of $109.69, marking a 46.06% increase over the past year and a 60% gain year-to-date. The company's robust performance is supported by strong financials, including 41% revenue growth in the last twelve months and a "GREAT" Financial Health Score from InvestingPro. Recent Q2 2026 results surpassed Wall Street expectations, with non-GAAP earnings of $2.28 per share and $481 million in revenue, leading to raised full-year guidance and positive analyst ratings.
Price-Driven Insight from (HALO) for Rule-Based Strategy
This article provides a price-driven analysis of Halozyme Therapeutics Inc. (HALO) for rule-based trading strategies, highlighting weak near-term sentiment but potential upside. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide investors. The analysis indicates strong mid and long-term signals despite current weak near-term sentiment.
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice
Halozyme Therapeutics (HALO) is highlighted as a strong momentum pick due to its favorable Zacks Momentum Style Score of B and a Zacks Rank of #2 (Buy). The article details HALO's significant price performance over various timeframes, outperforming its industry and the S&P 500, along with positive earnings estimate revisions, suggesting continued upward trajectory. Investors seeking short-term growth are advised to consider HALO based on these metrics.
Halozyme Therapeutics stock hits all-time high at 109.59 USD
Halozyme Therapeutics stock reached an all-time high of $109.59, reflecting significant growth over the past year, with a 49.33% increase. The company's recent strong Q2 2026 financial results, which surpassed analyst expectations for both earnings and revenue, contributed to this performance. Analysts have revised earnings upwards, and the stock is considered to have potential upside despite its rally, supported by positive data from a Phase 3 trial and increased price targets from firms like Citizens and H.C. Wainwright.
Halozyme (HALO) Stock Could Be Fully Priced On The Board Appointment
Halozyme Therapeutics (HALO) stock has shown strong returns over the past five years, but its current valuation suggests it may be fully priced, trading at a P/E ratio of 29.7x compared to the biotech industry average of 17.4x. While the recent board appointment of Dannielle Appelhans could support operational execution, the stock's mixed valuation score and premium P/E ratio indicate it is not a clear bargain. The article concludes that whether the stock maintains its premium depends on Halozyme's ability to meet earnings and operational expectations.
Halozyme Therapeutics (HALO) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Halozyme Therapeutics (HALO) is projected to announce Q1 earnings of $1.54 per share, marking a 38.7% increase year-over-year, with revenues expected to rise by 35.1% to $357.73 million. Analysts have slightly revised the consensus EPS estimate downwards by 0.7% over the past month. Key metrics anticipated include product sales of $102.82 million, royalties of $244.19 million, and collaboration agreement revenues of $10.88 million.
Halozyme (HALO) Stock Could Be Fully Priced On The Board Appointment
Halozyme Therapeutics stock has shown strong returns but appears overvalued based on market multiples and a P/E ratio higher than the biotech industry average. While the recent board appointment could support operational execution, the stock's current price already reflects significant positives, making it a mixed valuation case. Investors need to consider if future earnings and operational success will justify the current premium or if the multiple will adjust.
New Halozyme (NASDAQ: HALO) director logs zero stock in first ownership filing
Halozyme Therapeutics, Inc. (HALO) director Dannielle Appelhans filed an initial statement of beneficial ownership (Form 3) indicating her director status but reporting no specific equity holdings or transactions. The filing includes an Exhibit 24 Power of Attorney authorization. This neutral filing confirms her new role without detailing any stock ownership at this initial stage.
HALO Stock Rises 36% in a Month: Here's What You Should Know
Halozyme Therapeutics (HALO) shares have surged 36.4% in the past month, driven by investor confidence in its ENHANZE drug-delivery technology and strong second-quarter 2026 results. The company reported higher royalty payments from partners like J&J and argenx, leading to a 46.7% increase in royalty revenues and a 63% rise in product sales for the first half of 2026. Halozyme has also raised its full-year 2026 revenue and royalty guidance, indicating a positive outlook for continued growth.
Great Lakes Advisors LLC Purchases Shares of 36,039 Halozyme Therapeutics, Inc. $HALO
Great Lakes Advisors LLC has acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO), purchasing 36,039 shares valued at approximately $2.821 million during the second quarter. Other institutional investors have also adjusted their holdings in the biopharmaceutical company. The article details recent stock performance, earnings reports, analyst ratings, and insider transactions for Halozyme Therapeutics.
Halozyme Therapeutics (HALO) Adds A New Director, Is It 21% Overvalued?
Halozyme Therapeutics (HALO) recently elected Dannielle Appelhans to its Board of Directors, following strong share price returns, increased revenue, and ongoing buybacks. While analysts generally view HALO as 20.7% overvalued with a fair value of $86.89, a Discounted Cash Flow (DCF) model by Simply Wall St suggests a much higher fair value of $405.09. Investors are encouraged to review both perspectives to make informed decisions.
Aurora Investment Counsel Takes Position in Halozyme Therapeutics, Inc. $HALO
Aurora Investment Counsel has acquired a new stake of 18,233 shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO), valued at approximately $1.43 million, during the second quarter. This move is part of broader institutional investor activity, with several other firms also adjusting their holdings in the biopharmaceutical company. Meanwhile, company insiders, including Director Bernadette Connaughton and CEO Helen Torley, have recently sold shares, though institutional investors collectively own a significant 97.79% of the stock.
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock
Halozyme Therapeutics CEO Helen Torley sold 20,000 shares of the company's stock for over $2 million, executed under a pre-arranged Rule 10b5-1 trading plan. This transaction reduced her holdings by 2.54%. The company recently exceeded analyst estimates with strong quarterly earnings and revenue growth, leading to a "Moderate Buy" consensus rating from analysts.
Halozyme (NASDAQ: HALO) CEO sells tens of thousands of shares
Halozyme (NASDAQ: HALO) President and CEO Helen Torley exercised stock options and sold 60,000 common shares between August 17-19, 2026, under a pre-arranged Rule 10b5-1 trading plan. She exercised options at $18.41 per share and sold the shares in the high $90s to approximately $108 per share. These options were part of a grant from February 2018, set to expire in February 2028.
Halozyme Appoints Dannielle Appelhans to Board of Directors
Halozyme Therapeutics has appointed Dannielle Appelhans to its Board of Directors, effective August 14, 2026. She joins as a non-employee director with standard compensation and no initial committee assignments. Analysts currently rate HALO as a "Buy" with a $115.00 price target, and TipRanks' AI Analyst, Spark, also rates it as Outperform due to strong financial performance and positive earnings updates.
Halozyme Therapeutics (HALO) Adds A New Director, Is It 21% Overvalued?
Halozyme Therapeutics (HALO) recently appointed Dannielle Appelhans to its Board of Directors, following strong share price momentum and positive financial signals. While analysts' consensus fair value suggests the stock is 20.7% overvalued at $86.89, Simply Wall St's DCF model indicates a significantly higher fair value of $405.09. The article highlights both the optimistic outlook based on earnings guidance and buybacks, and concerns about concentration risk and patent challenges.
Diversify Advisory Services LLC Invests $2.77 Million in Halozyme Therapeutics, Inc. $HALO
Diversify Advisory Services LLC has acquired a new stake of 33,976 shares, valued at approximately $2.77 million, in Halozyme Therapeutics, Inc. This makes them one of many institutional investors, who collectively own 97.79% of the company. Halozyme Therapeutics recently reported strong quarterly earnings, beating analyst estimates, and has received a consensus "Moderate Buy" rating from analysts with an average price target of $91.20.
Foster & Motley Inc. Invests $2 Million in Halozyme Therapeutics, Inc. $HALO
Foster & Motley Inc. has acquired a new stake of $2 million in Halozyme Therapeutics (NASDAQ:HALO) during the second quarter, bringing institutional ownership to 97.79%. Halozyme Therapeutics reported strong quarterly results, surpassing EPS and revenue estimates, and provided positive fiscal 2026 EPS guidance, although insiders sold shares worth $3.14 million. Analyst sentiment for the biopharmaceutical company is generally positive, with a "Moderate Buy" consensus.
Halozyme Appoints Dannielle Appelhans to its Board of Directors
Halozyme Therapeutics, Inc. announced the election of Dannielle Appelhans to its Board of Directors. Ms. Appelhans brings over 20 years of executive leadership in the biotechnology and pharmaceutical industries, with significant expertise in operations, manufacturing, and supply chain management. Her experience will be a key asset as Halozyme continues to advance its drug delivery technology platforms and growth strategy.
Halozyme adds Dannielle Appelhans to board of directors
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced the appointment of Dannielle Appelhans to its board of directors. Appelhans, currently CEO of COUR Pharmaceuticals, brings extensive experience from her previous roles at Rubius Therapeutics, Inc., Novartis, McKinsey & Company, and Eli Lilly and Company. Her operational and manufacturing expertise is expected to support Halozyme's growth strategy.
Halozyme Therapeutics stock hits all-time high of 104.86 USD
Halozyme Therapeutics Inc. (HALO) stock reached an all-time high of $104.86, driven by strong investor confidence and positive market sentiment. The company reported impressive Q2 2026 financial results, surpassing Wall Street expectations with higher-than-estimated non-GAAP earnings and revenue, leading to an increased full-year outlook. Analysts at Citizens and H.C. Wainwright reiterated positive ratings and price targets, citing significant royalty revenue growth and positive clinical trial data.
Does Halozyme’s Raised 2026 Revenue Outlook And Aggressive Buybacks Change The Bull Case For HALO?
Halozyme Therapeutics reported strong Q2 2026 results with increased revenue and net income, alongside significant share repurchases of 13.45 million shares for $750 million. The company also raised its 2026 revenue guidance to between $1.84 billion and $1.91 billion, signaling management's confidence. This performance reinforces the investment narrative around ENHANZE-driven royalty growth, although investors still need to consider ongoing patent challenges and the concentration risk associated with key partners.
Halozyme (NASDAQ: HALO) insider lines up new stock sale after recent disposals
Halozyme Therapeutics insider Helen Torley has filed a Form 144, indicating a proposed sale of 240,000 shares of common stock with an aggregate market value of $23,678,400. This follows previous sales by Torley totaling 51,923 shares over the past three months, generating over $3.5 million. The filing also notes that Halozyme has 113,498,000 shares of common stock outstanding.
Horizon Investment Services LLC Buys Shares of 28,793 Halozyme Therapeutics, Inc. $HALO
Horizon Investment Services LLC has acquired 28,793 shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) worth approximately $2.25 million in the second quarter. This move is part of broader institutional investment, with collective ownership by institutional investors and hedge funds standing at 97.79%. Halozyme Therapeutics recently reported strong quarterly earnings, beating analyst estimates, and has a "Moderate Buy" consensus rating from analysts.
Chase Investment Counsel Corp Buys New Stake in Halozyme Therapeutics, Inc. $HALO
Chase Investment Counsel Corp has acquired a new stake of 26,000 shares in Halozyme Therapeutics, valued at approximately $2.0 million. This comes as institutional investors now collectively own 97.79% of the company. Despite insider selling activity, analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $91.20, with some analysts raising their targets even higher.
